Tribune Therapeutics AB, a Stockholm, Sweden- and Oslo, Norway-based biotechnology company dedicated to treating the root causes of fibrotic diseases, raised EUR 37m in seed and Series A funding.
The funding includes a EUR 23m Series A led by new investor LifeArc Ventures and joined by seed investors Novo Holdings, HealthCap, Innovestor’s Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor. In conjunction with the financing, LifeArc’s Baker and Industrifonden’s Jonathan Ilicki, MD, MBA, will join Tribune’s board.
The company intends to use the funds to advance a portfolio of therapies targeting central drivers of scar tissue formation.
Led by Georg Vo Beiske, PharmD, Chief Executive Officer and HealthCap Venture Partner, Tribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company is advancing multiple programs, including CCN5 mimic TRX-44.
The lead program, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF), a chronic fibrotic lung disease that leads to respiratory failure and death within three to five years of diagnosis. The Series A financing will prepare TRX-44 to begin clinical trials and will advance additional programs targeting the CCN protein family.
TRX-44 prevents scar formation by mimicking the structure and function of CCN5. CCN5 is an endogenous protein that naturally blocks the pro-fibrotic effects of other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to the fibrotic pathology. This approach is an evolution from blocking individual CCN proteins and their upstream activator, TGF-beta, and has the potential to combat a broader set of fibrotic diseases while avoiding the toxic side effects that have hampered the development of less targeted approaches.
FinSMEs
26/03/2025